RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with cisplatin and vinorelbine in treating patients with refractory or recurrent squamous cell cervical cancer that has not responded to local therapy.
OBJECTIVES: I. Determine the activity of cisplatin and vinorelbine in terms of response rate, duration of response, time to treatment failure, and survival in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. OUTLINE: This is a multicenter study. Patients receive vinorelbine IV over 6-10 minutes on days 1, 8, 15, and 22 and cisplatin IV over 4 hours beginning after completion of vinorelbine infusion on day 1. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 28-62 patients will be accrued for this study within approximately 20 months.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Enrollment
62
Chao Family Comprehensive Cancer Center
Orange, California, United States
MBCCOP - Hawaii
Honolulu, Hawaii, United States
Johns Hopkins Oncology Center
Baltimore, Maryland, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, United States
Cancer Center of Albany Medical Center
Albany, New York, United States
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States
CCOP - Upstate Carolina
Spartanburg, South Carolina, United States
Brookview Research, Inc.
Nashville, Tennessee, United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States